Med Ed Report briefs: February 2014

Murray Kopelow
Murray Kopelow

The Federation of State Medical Boards (FSMB) and FSMB Foundation are collaborating with several partners to provide state medical boards with resources to educate healthcare professionals on the prescribing of extended-release and long-acting opioid analgesics for patients with chronic pain.

Priya Wanchoo, MD, CCMEP, joined Haymarket Medical Education as VP and medical director. The grant development group will report to her, and she is tasked with helping HME to improve the quality of grant proposals, and contributing her medical perspective to myCME. (Haymarket Media publishes MM&M.)

ACCME president and CEO Murray Kope­low, MD (pictured), said a JAMA study that explored the relationship between “medical communication companies” and drug and device companies was “wrong” about ACCME-accredited providers. There are no such providers that are “supported mainly by drug and device companies,” Kopelow told Meetings­Net.com.

The Audio-Digest Foundation announced the release of original programs last month, including lectures in general surgery, family practice, emergency medicine and anesthesiology.

You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.